Newsletter Subject

Genetic Watchdogs Can Detect New COVID Variants Early

From

energyandcapital.com

Email Address

newsletter@energyandcapital.com

Sent On

Mon, Jan 17, 2022 08:15 PM

Email Preheader Text

These humble scientists have been silently keeping watch against the planet’s most devastating

These humble scientists have been silently keeping watch against the planet’s most devastating diseases. But their work has never been quite this important — or this urgent… These humble scientists have been silently keeping watch against the planet’s most devastating diseases. But their work has never been quite this important — or this urgent... [Energy and Capital logo] Genetic Watchdogs Can Detect New COVID Variants Early [Luke Sweeney Photo] By [Luke Sweeney]( Written Jan 17, 2022 The very first cases of the omicron COVID variant were identified in Durban, South Africa. Scientists at the Center for Epidemic Response and Innovation (CERI) identified the outbreak, recorded its unique genetic sequence, and then immediately sounded the alarm. [1] CERI’s lightning-quick response time and strict infection control standards meant that less than a week passed before the entire world was alerted to omicron’s contemptible existence. Think about that. Less than seven days passed between discovery and classification. And even that feat of medical and bureaucratic magic wasn't enough. The virus was already present on three continents by the time the world reluctantly snapped to attention. Within a few months, the new variant had swept across the planet. Businesses went into lockdown, governments handed out various travel bans, and the stock market took a dizzying nosedive. We all know the drill at this point. It’s not the first time, and I’m willing to bet it won't be the last. Meet Your New Waitress: Rosie Five million workers have vanished from the workforce, with many establishments having closed for good. But not this restaurant outside of Boston. The solution to the labor shortage could easily be this robot: It’s called Rosie, and it works as the restaurant’s server. You can already find robots like Rosie working in restaurants, hotels, casinos, and retirement homes throughout the U.S. Robots will change everything, and they’re charging toward us at full speed. And I know of three companies on the leading edge of the robot revolution. [Getting in now is like buying Dell, Apple, and Microsoft back at the beginning of the computer revolution.]( Various countries slapped reactionary travel bans on South Africa and its neighbors. At that point, their efforts were laughable, like trying to catch smoke with their bare hands. [2] So what has this taught us? For one, even a near-instant response time isn't enough to curb the spread of a new variant. Omicron spreads like lightning through any path it can find. The scientific community thinks it has a solution. Now we just need to see if it’s fast enough to match its target. Enter the (Previously Ignored) Field of Genetic Surveillance These dedicated scientists have been silently keeping watch over the planet’s diseases for years now. And their work has never been as important — or as urgent. The concept of genetic surveillance is self-explanatory. The WHO and a network of medical facilities around the globe are currently acting as watchdogs, constantly analyzing new viral material for the tiniest molecular changes. [3] If any suspicious mutations are detected, the lab can immediately notify the rest of the world. Sharing the genetic sequence of each virus can help prepare treatments and track the spread of each variant. Whether they can actually do anything at that point is another story. This virus works on a very aggressive timetable. Surveillance is the first step, of course, but the real uphill battle is launching an effective, large-scale response. And even then, it might still be too late to contain an outbreak. Omicron’s rise to fame in South Africa is a perfect example. The medical community did its job flawlessly, while the political arm lazily drafted a few ineffective travel bans and called it day. All of this makes one thing painfully obvious: What we’re doing isn't working. A huge portion of the world is still stuck bickering about vaccines, and another chunk wants to keep lockdowns going indefinitely. We’ve been isolated, lied to, and ignored for multiple years now; meanwhile, the virus shows no signs of slowing down. The world’s governments' incompetence is on full display, and it’s shameful. We Need a World Beyond Vaccines In the U.S., the Supreme Court just struck down Biden’s proposed vaccine mandate. Private companies will not have to require proof of vaccination or evidence of a negative PCR test. The #1 Stock to End COVID (Not Pfizer) While companies like Moderna brought us vaccines... Big and small companies all over the globe are STILL working 24/7 to create a successful COVID-19 treatment. But one company’s breakthrough COVID-killing nasal spray is about to beat them all.This company is not some big pharma giant like Pfizer or Merck. It’s TINY. But it has the power to end COVID once and for all... And could hand you profits large enough to help you retire wealthy. [Take a look at this groundbreaking treatment for yourself.]( I’m sure he will try some other method of imposing his will on the rest of the country, but for now only healthcare workers and federally funded businesses are obligated to get the jab. The jury is still out on federal contractors. If he were still functioning at 100% cognitive capacity, Biden would take this as a sign. The world doesn't trust the current vaccine technology, and it has no obligation to do so. After all, the government doesn't exactly have a perfect track record in that department. The list of horrifying medical experiments in the world’s history is endless. On a smaller scale, a few companies have enough foresight to see past vaccines. Pharma giants like Pfizer are already dug in too deep. They have no interest in giving up their COVID treatment monopoly anytime soon. Luckily, an entire ecosystem of development has blossomed under the pharmaceutical industry's nose. And [one company]( in particular is dead set on breaking up this newly formed monopoly. [Check out our free research presentation on this tiny $1-per-share company here](, before it grows up to become the next biotech giant. Good investing, To your wealth, Luke Sweeney Contributor, Energy and Capital Luke’s technical know-how combined with an insatiable scientific curiosity has helped uncover some of our most promising leads in the tech sector. He has a knack for breaking down complicated scientific concepts into an easy-to-digest format, while still keeping a sharp focus on the core information. His role at Angel is simple: transform piles of obscure data into profitable investment leads. When following our recommendations, rest assured that a truly exhaustive amount of research goes on behind the scenes.. Browse Our Archives [Oil and Gas Stocks Crushed Gold Stocks in 2021]( [The Real Winner in "Greenwashing" Our World]( [Inflation, Car Prices, and Rate Hikes]( [Hook Echoes and Quantum Tornadoes]( [Stop Watching Others Bank Triple Digits While You Sit on 10% Returns]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here]( and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Energy and Capital, Copyright © 2022, Angel Publishing LLC. All rights reserved. 3 E Read Street, Baltimore, MD 21202. Your privacy is important to us – we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment advice. Read our [Details and Disclosures.]( ---------------------------------------------------------------

Marketing emails from energyandcapital.com

View More
Sent On

08/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Sent On

04/12/2024

Sent On

04/12/2024

Sent On

02/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.